Search the Newsreel

ALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

ALX Oncology Holdings Inc has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement of these results, directing readers to access the full report on TradingView, which aggregates content from Reuters and other news sources.

DigitalX Cancels Over 92 Million Shares in On-Market Buy-Back

DigitalX Limited Cancels 92.25 Million Shares Under On-Market Buy-Back

ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary

ALX Oncology Holdings Inc. reported a reduced net loss of $17.97M in Q2 2026, down from $25.95M in Q2 2025, with diluted EPS improving to $(0.13) from $(0.49). This improvement is attributed to lower operating expenses resulting from streamlined clinical programs. The company highlighted …

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (Nasdaq: ALXO) announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its clinical programs, including the ASPEN-09-Breast trial for evorpacept and the Phase 1 trial for ALX2004. The company reported a strengthened balance sheet, with cash …

DigitalX Limited Buys Back 37,113 Shares in Daily On-Market Update

ALX Oncology (NASDAQ:ALXO) Issues Earnings Results

Atlas Arteria (ASX:ALX) Slides as Infrastructure Investors Turn Defensive

DigitalX Updates ASX on Progress of On-Market Share Buy-Back

ALX Oncology (ALXO) Projected to Post Earnings on Tuesday

ALX Oncology (NASDAQ:ALXO) is expected to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts projecting a loss of $0.15 per share. The company previously missed Q1 estimates, reporting a $0.17 per share loss. ALXO shares recently saw a …

ALEXANDERS INC 2Q 2026: Revenue $54.7M, EPS $30.24— 10-Q Summary

ALEXANDERS INC (ALX) reported strong second-quarter 2026 results, with revenue of $54.7 million and diluted EPS of $30.24, significantly up from the prior year. This increase was primarily driven by a $148.0 million gain from the sale of its Rego Park I property. The …

Alexander’s Q2 Income Includes $148M Rego Park I Sale Gain

Alexander's (NYSE: ALX) reported a significant increase in Q2 2026 net income to $155.4 million, primarily driven by a $148.0 million gain from the sale of its Rego Park I property. While this sale boosted net income, the company's Funds From Operations (FFO) showed …

Alexander's (NYSE:ALX) Shares Gap Up Following Earnings Beat

Alexander's Inc (ALX) Shares Fall 4.1% -- GF Value Says Still Overvalued

Alexander's Inc (ALX) shares dropped 4.1% to $255.00, placing it 24.5% above its GF Value™ of $204.78, indicating it is overvalued. The company's GF Score™ of 64/100 suggests above-average quality, but with concerning financial strength and low growth scores, alongside insider selling activity, investors …

ALXO|ALX Oncology Holdings Inc|Price:1.950|Chg%:-0.040

This article provides a comprehensive stock analysis of ALX Oncology Holdings Inc (ALXO), highlighting its relatively weak fundamentals but high growth potential and fair valuation within the Biotechnology & Medical Research industry. The company's lead product candidate, evorpacept, is a CD47 blocking therapeutic, and …

Alexander’s Declares Quarterly $4.50 Dividend on Common Shares

Alexander’s (NYSE: ALX) has declared a regular quarterly dividend of $4.50 per common share. This dividend is payable on August 28, 2026, to stockholders of record as of August 10, 2026. Alexander's is a real estate investment trust that owns four properties in New …

ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of ALX Oncology Holdings Inc (ALXO), noting its weak financial status and low operating efficiency with a score of 5.40 out of 385 in the Biotechnology & Medical Research industry. It highlights that relevant financial data for Quality …

ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC

venBio Partners LLC significantly increased its stake in ALX Oncology Holdings Inc. ($ALXO) by 32.8% in Q1, acquiring over 3.18 million additional shares. This makes ALXO the third-largest holding in venBio's portfolio, representing 9.58% of ALXO's total shares. Despite the company missing its latest …

ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for ALX Oncology Holdings Inc (ALXO), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It displays current stock information including the market cap and P/E TTM. …

BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO)

BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership of 5.4% in ALX Oncology Holdings Inc. This stake amounts to 7,327,850 common shares, with BlackRock exercising sole voting power over 7,231,560 shares and sole dispositive power over all beneficially owned shares. The …

ALX Oncology Holdings Inc (ALXO) Cash Flow

This article provides a detailed cash flow statement for ALX Oncology Holdings Inc (ALXO), covering quarterly and annual data with year-over-year changes across operating, investing, and financing activities. It breaks down various components such as net income, changes in working capital, capital expenditures, and …

2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC

Orbimed Advisors LLC purchased 2.87 million shares of ALX Oncology Holdings Inc. ($ALXO) in the first quarter, a stake valued at approximately $5.75 million. This acquisition makes Orbimed Advisors LLC the owner of about 2.13% of ALX Oncology. Other institutional investors collectively hold 97.97% …

ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a detailed historical overview of ALX Oncology Holdings Inc (ALXO) stock, focusing on dividend payouts and stock splits. It indicates that ALXO has not distributed any dividends over the past five years. The page also presents current stock performance data and …

ALXO Balance Sheet

This article provides a detailed balance sheet analysis for ALX Oncology Holdings Inc (ALXO), presenting quarterly and annual financial data spanning several years for various assets, liabilities, and shareholders' equity categories. It allows users to evaluate the company's financial health and understand key financial …

ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010

ALX Oncology Holdings Inc. (ALXO) is a clinical-stage biotechnology company with a strong growth potential, despite relatively weak fundamentals. The stock is considered fairly valued and has a high institutional ownership. Analysts rate it as a "Buy" with a target price of $4.60, indicating …

Alx Oncology Holdings, Inc. (ALXO) Q3 2025 Earnings Report - Results, Call & Slides

Alx Oncology Holdings (ALXO) released its Q3 2025 earnings report, missing consensus EPS estimates by $0.04 with an actual EPS of -$0.41, compared to a consensus of -$0.37. The company's revenue for Q3 2025 was $0.00, meeting expectations. ALXO's next earnings date is estimated …

DigitalX Limited Executes On-Market Share Buy-Back, Acquiring 5 Million Shares on 21 July

Atlas Arteria’s 7.86% Yield: Could Toll-Road Cash Flows Drive Reliable Income?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year price target of $4.60. The clinical-stage biopharmaceutical company, focused on immuno-oncology with its lead candidate evorpacept, recently reported quarterly earnings of -$0.17 per share, missing estimates. …

ALX Oncology (ALXO) Status Update Summary

ALX Oncology is advancing its lead drug evorpacept through multiple FDA registration paths, targeting significant oncology markets with new clinical trials in breast and colorectal cancer and expecting initial data readouts in 2025-2026. The company has implemented cost-cutting measures, including a 30% workforce reduction, …

DigitalX Limited Accelerates Share Buy-Back Programme With 20 Million Shares Repurchased on Single Trading Day

Alexanders Inc stock hits 52-week high at 281.74 USD By Investing.com

Alexanders Inc. (ALX) stock recently reached a new 52-week high of $281.74, marking a 16.24% increase over the past year and a 32% year-to-date return. The company also offers a 6.5% dividend yield and has maintained consistent payments for 17 years. This milestone follows …

DigitalX delivers milestone quarter